SCHEMBL4348188

SCHEMBL4348188

COc1c(C(=O)NCCCN2CCCC2=O)ccc2[nH]nc(-c3cc4ccccc4o3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
RCE1 Q9Y256 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
KMT2A Q03164 2/20 0.46
DRD2 P14416 2/20 0.45
DRD3 P35462 2/20 0.45
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.41
HTR1A P08908 1/20 0.41
DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335955 0.86 RCE1 (0.54) L3MBTL1RCE1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4332582 0.84 L3MBTL1 (0.51) L3MBTL1RCE1SMN1; SMN2KDM4EKMT2A
SCHEMBL4334565 0.82 LMNA (0.41) SMN1; SMN2KDM4EKMT2ADRD2DRD3
SCHEMBL4335954 0.81 L3MBTL1 (0.51) L3MBTL1RCE1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4336829 0.80 KDM4E (0.43) SMN1; SMN2KDM4EKMT2ADRD2DRD3
SCHEMBL2866722 0.80 GSK3B (0.41) DRD2DRD4
SCHEMBL4341547 0.78 BRD4 (0.46) L3MBTL1SMN1; SMN2KDM4EKMT2ADRD2
SCHEMBL2862928 0.78 PIP5K1C (0.46) L3MBTL1KDM4EKMT2AALDH1A1MEN1
SCHEMBL4334418 0.77 ALDH1A1 (0.54) SMN1; SMN2KDM4EKMT2AALDH1A1MEN1
SCHEMBL4341426 0.77 GAA (0.50) SMN1; SMN2KDM4EKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 L3MBTL1 2399/4885RCE1 1933/4885SMN1; SMN2 4812/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 L3MBTL1 2399/4885RCE1 1933/4885SMN1; SMN2 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.